PAVmed (PAVM) Sees Strong Trading Volume

PAVmed Inc (NASDAQ:PAVM) saw unusually-high trading volume on Wednesday . Approximately 1,938,427 shares were traded during mid-day trading, an increase of 756% from the previous session’s volume of 226,576 shares.The stock last traded at $1.05 and had previously closed at $1.03.

Separately, Maxim Group restated a “buy” rating and issued a $3.00 target price on shares of PAVmed in a report on Monday, January 14th.

The firm has a market cap of $28.50 million, a PE ratio of -2.02 and a beta of 0.01.

A hedge fund recently raised its stake in PAVmed stock. Vanguard Group Inc grew its holdings in PAVmed Inc (NASDAQ:PAVM) by 289.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 370,712 shares of the company’s stock after purchasing an additional 275,512 shares during the period. Vanguard Group Inc owned approximately 1.40% of PAVmed worth $482,000 as of its most recent SEC filing. Institutional investors own 1.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “PAVmed (PAVM) Sees Strong Trading Volume” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at


PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device.

Further Reading: How do taxes affect a CDs total return?

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.